Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Belluscura PLC - London-based medical device developer - Signs a manufacturing master supply agreement with InnoMax Medical Technology Ltd, a joint venture between MexNerva Technology Services Ltd and China's National Centre for Advanced Medical Devices. The agreement is for the manufacture of the X-PLO2R portable oxygen concentrator in China. Belluscura says the agreement will more than double its manufacturing capacity next year. Commercialisation and distribution in Asia is expected to occur no later than the first quarter of 2023. The agreement has an initial duration of three years. Belluscura does not disclose the financial details.
Current stock price: 111.00 pence, up 12% in London
12-month change: more than doubled from 53.00p
Copyright 2022 Alliance News Limited. All Rights Reserved.